Becton, Dickinson and Company (BDX) Shares Sold by Candriam Luxembourg S.C.A.

Candriam Luxembourg S.C.A. reduced its holdings in Becton, Dickinson and Company (NYSE:BDX) by 39.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 55,544 shares of the medical instruments supplier’s stock after selling 36,026 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Becton, Dickinson and were worth $10,884,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Almanack Investment Partners LLC. acquired a new stake in shares of Becton, Dickinson and in the first quarter valued at about $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in shares of Becton, Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after purchasing an additional 240 shares during the last quarter. Parkside Financial Bank & Trust grew its position in shares of Becton, Dickinson and by 8.1% in the second quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock valued at $133,000 after purchasing an additional 51 shares during the last quarter. Harfst & Associates Inc. grew its position in shares of Becton, Dickinson and by 46.4% in the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after purchasing an additional 221 shares during the last quarter. Finally, Financial Architects Inc grew its position in shares of Becton, Dickinson and by 8.0% in the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after purchasing an additional 54 shares during the last quarter. 86.01% of the stock is currently owned by institutional investors.

A number of equities research analysts recently weighed in on the company. Stifel Nicolaus reissued a “buy” rating and set a $245.00 target price on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Royal Bank Of Canada reissued a “sector perform” rating and set a $230.00 target price (up from $210.00) on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Morgan Stanley lifted their target price on Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Wells Fargo & Company reissued a “positive” rating and set a $235.00 target price (up from $225.00) on shares of Becton, Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Finally, Zacks Investment Research raised Becton, Dickinson and from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. Five analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $213.47.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at $220.00 on Tuesday. The company has a debt-to-equity ratio of 1.48, a quick ratio of 5.01 and a current ratio of 5.56. The firm has a market capitalization of $49,889.07, a P/E ratio of 23.10, a price-to-earnings-growth ratio of 1.72 and a beta of 1.04. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $225.23.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The company’s quarterly revenue was down 2.0% on a year-over-year basis. During the same period in the previous year, the business earned $2.12 earnings per share. equities research analysts predict that Becton, Dickinson and Company will post 10.63 EPS for the current fiscal year.

In other news, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the transaction, the insider now owns 95,781 shares in the company, valued at $19,517,294.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Stephen Sichak sold 11,787 shares of Becton, Dickinson and stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the completion of the transaction, the insider now owns 14,038 shares of the company’s stock, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. Insiders sold 47,038 shares of company stock valued at $9,480,225 in the last quarter. 1.40% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Becton, Dickinson and Company (BDX) Shares Sold by Candriam Luxembourg S.C.A.” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://sportsperspectives.com/2017/11/14/becton-dickinson-and-company-bdx-shares-sold-by-candriam-luxembourg-s-c-a.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply